December 27, 2022
Authored and Edited by Jason Y. Zhang, M.D.; Christina Ji-Hye Yang; Esther H. Lim
In ADASA Inc. v. Avery Dennison Corp., No. 2022-1092 (Fed. Cir. Dec. 16, 2022), the Federal Circuit affirmed in part the district court’s grant of summary judgment in favor of ADASA under 35 U.S.C. § 101, but reversed the determination that the claim-at-issue is neither anticipated nor obvious.
Claim 1 of U.S. Patent No. 9,798,967 is directed to a system for commissioning RFID tags for unique object identification and tracking. The Federal Circuit held that the claim is not directed to an abstract idea, but rather to a specific, hardware-based data structure improving upon RFID encoding. However, the Federal Circuit reversed the district court’s grant of summary judgment based on lack of anticipation and non-obviousness, holding that the district court read the prior art too narrowly. Even though the prior art references discussed the claimed concepts differently, their disclosures were sufficient to create a genuine dispute of fact. The Federal Circuit affirmed the district court’s decision not to include a lumpsum option for damages in the jury verdict form and to exclude Avery’s licenses and expert testimony from evidence. The Federal Circuit also vacated discovery sanctions against Avery.
Copyright © 2022 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.